| 1 |
34820006 | Tanshinone IIA potentiates the efficacy of imatinib by regulating the AKT-MDM2-P53 signaling pathway in Philadelphia chromosome-positive acute lymphoblastic leukemia. | 2022 Jan |
2 |
| 2 |
32084420 | Enhanced proliferation inhibition and apoptosis in glioma cells elicited by combination of irinotecan and imatinib. | 2020 May 5 |
3 |
| 3 |
32116712 | Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. | 2020 |
2 |
| 4 |
32655803 | The Lyn-SIRT1 signaling pathway is involved in imatinib resistance in chronic myeloid leukaemia. | 2020 |
3 |
| 5 |
28027118 | Gain of TP53 Mutation in Imatinib-treated SDH-Deficient Gastrointestinal Stromal Tumor and Clinical Utilization of Targeted Next-generation Sequencing Panel for Therapeutic Decision Support. | 2018 Sep |
1 |
| 6 |
29115375 | Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib. | 2018 Jan |
2 |
| 7 |
29370077 | p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib. | 2018 Jan 25 |
4 |
| 8 |
29451912 | Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment. | 2018 |
1 |
| 9 |
30103756 | Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance. | 2018 Aug 13 |
2 |
| 10 |
28410239 | Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines. | 2017 Jun 6 |
1 |
| 11 |
28661474 | Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers. | 2017 Jun 29 |
1 |
| 12 |
29046392 | Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL. | 2017 Dec 6 |
1 |
| 13 |
27281222 | Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. | 2016 Jun 16 |
2 |
| 14 |
25791792 | Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib. | 2015 Dec |
1 |
| 15 |
26881646 | A complex three-way translocation with deletion of the TP53 gene in a blast crisis chronic myeloid leukemia patient. | 2015 Oct-Dec |
1 |
| 16 |
23818300 | MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib. | 2014 Dec |
3 |
| 17 |
24177958 | c-ABL tyrosine kinase modulates p53-dependent p21 induction and ensuing cell fate decision in response to DNA damage. | 2014 Feb |
1 |
| 18 |
24913304 | A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels. | 2014 Oct |
1 |
| 19 |
23433851 | Arginine homozygosity in codon 72 of p53 correlates with failure to imatinib response in chronic myeloid leukemia. | 2013 Mar |
4 |
| 20 |
22340598 | Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. | 2012 Feb 14 |
1 |
| 21 |
22662219 | p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. | 2012 |
1 |
| 22 |
20094798 | Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. | 2010 May |
2 |
| 23 |
19150257 | HCT116 cells deficient in p21(Waf1) are hypersensitive to tyrosine kinase inhibitors and adriamycin through a mechanism unrelated to p21 and dependent on p53. | 2009 Mar 1 |
2 |
| 24 |
19291793 | Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells. | 2009 Jul 1 |
8 |
| 25 |
19903850 | Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data. | 2009 Dec 1 |
1 |
| 26 |
19934315 | Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity. | 2009 Dec 15 |
6 |
| 27 |
18413724 | BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. | 2008 Apr 15 |
1 |
| 28 |
18474303 | Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia. | 2008 May |
1 |
| 29 |
17569822 | Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. | 2007 Sep |
3 |
| 30 |
16651519 | Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. | 2006 May 9 |
3 |
| 31 |
16741250 | CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. | 2006 Nov 15 |
1 |
| 32 |
16227678 | Tyrosine kinase inhibitor STI571 (Imatinib) cooperates with wild-type p53 on K562 cell line to enhance its proapoptotic effects. | 2005 |
3 |
| 33 |
15048068 | Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571. | 2004 |
1 |
| 34 |
15467443 | Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage. | 2004 Sep |
4 |
| 35 |
12679488 | The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. | 2003 Apr |
1 |
| 36 |
12928501 | Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl. | 2003 Sep 2 |
1 |
| 37 |
11606405 | Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells. | 2001 Oct 15 |
1 |